DF
Therapeutic Areas
Mesoblast Pipeline
| Drug | Indication | Phase |
|---|---|---|
| RYONCIL (remestemcel-L) | Pediatric Steroid-Refractory Acute Graft-Versus-Host Disease | Approved |
| REVASCOR (rexlemestrocel-L) | Advanced Chronic Heart Failure (HFrEF) | Phase 3 |
| MPC-06-ID | Chronic Low Back Pain due to Degenerative Disc Disease | Phase 3 |
| Remestemcel-L | Acute Respiratory Distress Syndrome (ARDS) | Phase 3 |
Leadership Team at Mesoblast
DS
Dr. Silviu Itescu
Founder & Chief Executive Officer
JM
Joshua Muntner
Chief Commercial Officer (U.S.)
DD
Dr. Donna Skerrett
Chief Medical Officer (U.S.)
JJ
John J. Smith
Chief Financial Officer
PS
Professor Sir Graham L. Patrick
Board Director
DJ
Dr. John J. L. Ho
Board Director